pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 30·1 min read
save

Virtual mental-health firms accelerate AI chatbot development using therapy session data

Jun 30, 2026·read at Endpoints ↗Neutral

People are turning to artificial intelligence for daily tasks, companionship and emotional support, prompting virtual mental‑health providers to explore AI solutions.

Companies that were previously hesitant about AI are now racing to create their own chatbots in order to remain competitive in the market.

These new chatbots are being trained on actual therapy session content, a practice that raises questions about data privacy and the ethical use of patient information.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “How mental health chatbots are trained on therapy sessions”

read at Endpoints ↗
85 words · retrieved Jul 1
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
Psychiatry & CNS2

related stories

  • Apr 27STAT+: Astellas retries XLMTM gene therapy after deathsSTAT
  • Apr 27What’s the true risk for eating disorders with GLP-1s?STAT
  • Apr 27STAT+: Intellia says CRISPR-based treatment for rare disease reduced swelling attacks in pivotal trialSTAT
  • Apr 27STAT+: Oruka’s long-acting psoriasis therapy posts strong results in mid-stage studySTAT
  • Apr 27STAT+: Veradermics’ hair loss drug succeeds in late-stage trialSTAT